Perceived medication benefits and their association with interest in using inhaled insulin in type 2 diabetes: A model of patients' cognitive framework

Patient Preference and Adherence

Volumn 5, Issue , 2011, Pages 255-265

  Peyrot, Mark ^a,b   Rubin, Richard R ^b  

^a LOYOLA UNIVERSITY MARYLAND   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Inhaled insulin; Medication benefits; Patient preference; Type 2 diabetes

Indexed keywords

INSULIN;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL EVALUATION; DRUG EFFICACY; FEMALE; GLYCEMIC CONTROL; HEALTH CARE NEED; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; NEEDS ASSESSMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ATTITUDE; PATIENT PREFERENCE; RISK BENEFIT ANALYSIS; SIDE EFFECT; UNITED STATES; WEIGHT;

EID: 84856936920     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: 10.2147/PPA.S18799     Document Type: Article

References (27)

1. World Health Organization. Adherence to long-term therapies. Geneva, Switzerland: WHO; 2003.
2. Shah NR, Hirsch AG, Zacker C, et al. Factors associated with first-fill adherence rates for diabetic medications: a cohort study. J Gen Intern Med. 2009;24(2):233-237.
3. Cramer J. A systematic review of adherence with medications for diabetes. Diabetes Care. 2004;27(9):1218-1224.
4. Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med. 2005;118(Suppl 5A):27S-35S.
5. Rubin RR, Peyrot M. Factors affecting use of insulin pens by patients with type 2 diabetes. Diabetes Care. 2008;31(3): 430-432.
6. Kravitz RL, Epstein RM, Feldman MD, et al. Influence of patients' requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. JAMA. 2005;293(16):1995-2002.
7. Peyrot M, Rubin RR. Physician perception and recommendation of insulin pens for patients with type 2 diabetes. Curr Med Res Opin. 2008;24(8):2413-2422.
8. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs study (DAWN). Diabetes Care. 2005;28(11):2673-2679.
9. Rubin RR, Peyrot M. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/ soluble aspart) versus alternative treatment strategies. Diabetes Care. 2004;27(10):2495-2497.
10. Peyrot M, Rubin RR. Validity and reliability of an instrument for assessing health-related quality of life and treatment preference: the Insulin Delivery System Rating Questionnaire. Diabetes Care. 2005;28(1):53-58.
11. Peyrot M, Rubin RR. How does treatment satisfaction work?: modeling determinants of treatment satisfaction and preference. Diabetes Care. 2009;32(8):1411-1417.
12. Rubin RR, Peyrot M, Kruger D, Travis L. Barriers to insulin injection therapy: patient and health care provider perspectives. Diabetes Educator. 2009;35(6):1014-1022.
13. Peyrot M, Rubin RR, Kruger D, Travis L. Correlates of insulin injection omission. Diabetes Care. 2010;33(2):243-248.
14. Peyrot M, Rubin RR. Effect of Technosphere inhaled insulin on quality of life and treatment satisfaction. Diabetes Technol Therapeutics. 2010; 12(1):49-55.
15. Freemantle N, Blonde L, Duhot D, et al. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care. 2005;28(2):427-428.
16. Peyrot M, Rubin RR. Perceived medication benefits and their association with interest in using inhaled insulin in type 2 diabetes: a model of patients' cognitive framework. Diabetes. 2010;59(Suppl 1):A52.
17. Rosenstock J, Bergenstal R, DeFronzo RA, et al. Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naïve type 2 diabetes suboptimally controlled with oral agents. Diabetes Care. 2008;31(11):2177-2182.
18. Rosenstock J, Lorber DL, Gnuidi L, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomized trial. Lancet. 2010; 375(9733):2244-2253.
19. Amin V, Boss AH, Petrucci RE, et al. Pulmonary functions (over 2 years) in diabetic subjects treated with AfresaTM or usual antidiabetic treatment. Diabetes. 2009;58(Suppl 1):A153.
20. Heinemann L, Heise T. Current status of the development of inhaled insulin. Br J Diabetes Vascular Dis. 2004;4(5):295-301.
21. Peyrot M, Skovlund S, Landgraf R. Epidemiology and correlates of weight worry in the multi-national Diabetes Attitudes, Wishes and Needs (DAWN) Study. Curr Med Res Opin. 2009;25(8):1985-1993.
22. Makine C, Karsidag C, Kadioglu P, et al. Symptoms of depression and diabetes-specific emotional distress are associated with a negative appraisal of insulin therapy in insulin-naïve patients with type 2 diabetes mellitus. A study from the European Depression in Diabetes [EDID] Research Consortium. Diabet Med. 2009;26(1):28-33.
23. Peyrot M, McMurry JF, Hedges R. Living with diabetes: the role of personal and professional knowledge in symptom and regimen management. In: Roth J, Conrad P, editors. Research in the Sociology of Health Care, Vol 6. Greenwich, CT: JAI Press; 1987:107-146.
24. Cox DJ, Irvine A, Gonder-Frederick L, et al. Fear of hypoglycemia: quantification, validation, and utilization. Diabetes Care. 1987;10(5):617-621.
25. Del Prato S, Blonde L, Martinez L, et al. The effect of the availability of inhaled insulin on glycaemic control in patients with type 2 diabetes failing on oral therapy: the evaluation of Exubera as a therapeutic option on insulin initiation and improvement in glycaemic control in clinical practice. Diabet Med. 2008;25(6):662-670.
26. Guimarães C, Marra CA, Gill S, et al. A discrete choice experiment evaluation of patients' preferences for different risk, benefit, and delivery attributes of insulin therapy for diabetes management. Patient Prefer Adherence. 2010;4:433-440.
27. Rubin RR, Peyrot M. Factors associated with physician perceptions of and willingness to recommend inhaled insulin. Current Med Res Opin. 2011;27(2):285-294.